Drug-Drug Interaction Potential of SH-1028, a Third-generation EGFR-TKI: In Vitro and Clinical TrialsXiaoli Lia, †, Yuyan Liub, †,Yuanyuan Xua, d , †, Jiaxiang Dinga, c, Cuixia Hea, d, Minhui Zhua,d,Yue Sua, c , Xiangdi Zhaoa, d, Ying Wanga, d, Rongfang Shana, d, Yuanyuan Liua, Bingyan Liua, Yuzhou Dinga, Jing Xiea, Fei Guoa, Huan Zhoua, c,d, *, Zhiqiang Wange, *, Hongtao Lia, *a National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233009, Chinab Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, Chinac School of Public Foundation, Bengbu Medical College, Bengbu 233030, Chinad School of Pharmacy, Bengbu Medical College, Bengbu 233030, Chinae School of Pharmaceutical Sciences, China Pharmaceutical University, Nanjing 210009, China* Co-corresponding authors: Huan Zhou, Zhiqiang Wang and Hongtao Li† These authors made equal contributions to this work.